NATiV3: A randomized, double blind, placebo-controled, multicentre, Phase 3 study evaluating long term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosi